NEWS: #AbeonaTherapeutics' Zevaskyn, a 'celltherapy based on engineered keratinocytes harvested from patients, has been approved in the US as a treatment for the #rareskindisorder recessive dystrophic epidermolysis bullosa (DEB).
Abeona prices rare cell disorder gene therapy at $3.1m
Abeona Therapeutics' Zevaskyn has been approved in the US as a treatment for the rare skin disorder recessive dystrophic epidermolysis bullosa (DEB).
buff.ly
April 30, 2025 at 11:00 AM
NEWS: #AbeonaTherapeutics' Zevaskyn, a 'celltherapy based on engineered keratinocytes harvested from patients, has been approved in the US as a treatment for the #rareskindisorder recessive dystrophic epidermolysis bullosa (DEB).